Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.48 USD | -8.64% | -9.20% | -43.94% |
Financials (USD)
Sales 2024 * | 10.54M | Sales 2025 * | 14.69M | Capitalization | 71.99M |
---|---|---|---|---|---|
Net income 2024 * | -51M | Net income 2025 * | -62M | EV / Sales 2024 * | 6.83 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 4.9 x |
P/E ratio 2024 * |
-1.48
x | P/E ratio 2025 * |
-1.47
x | Employees | 53 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.32% |
Latest transcript on Cue Biopharma, Inc.
1 day | -8.64% | ||
1 week | -9.20% | ||
Current month | -9.20% | ||
1 month | -22.51% | ||
3 months | -25.25% | ||
6 months | -52.10% | ||
Current year | -43.94% |
Managers | Title | Age | Since |
---|---|---|---|
Daniel Passeri
CEO | Chief Executive Officer | 63 | 16-07-31 |
Anish Suri
PSD | President | 50 | 18-06-30 |
Kerri-Ann Millar
DFI | Director of Finance/CFO | 54 | 17-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Driscoll
BRD | Director/Board Member | 73 | 18-06-25 |
Daniel Passeri
CEO | Chief Executive Officer | 63 | 16-07-31 |
Peter Kiener
BRD | Director/Board Member | 72 | 16-02-29 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 2 M€ | -.--% | ||
0.00% | 32 M€ | +4.30% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 1.48 | -8.64% | 228,377 |
24-06-06 | 1.62 | -1.82% | 114,113 |
24-06-05 | 1.65 | +5.77% | 238,446 |
24-06-04 | 1.56 | -5.45% | 300,778 |
24-06-03 | 1.65 | +1.23% | 302,197 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-43.94% | 71.99M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- CUE Stock